Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Penault-Llorca

Showing results (71-80 of 141) with videos related to

Pageof 15
Sort By:
ESMO Gastrointestinal Oncology|February 6, 2026
High prevalence of NTRK fusions in sporadic dMMR/MSI mCRC RAS/RAF wild-type: an opportunity for a post-immune checkpoint inhibitors progression rescue strategyM Svrcek, A Cayre, T Samaille, et al.
Biochemical and Biophysical Research Communications|July 13, 2005
Leptin: a proliferative factor for breast cancer? Study on human ductal carcinomaF Caldefie-Chézet, M Damez, M de Latour, et al.
International Journal of General Medicine|April 3, 2010
Role of neo-adjuvant hormonal therapy in the treatment of breast cancer: a review of clinical trialsCatherine Abrial, Xavier Durando, Marie-Ange Mouret-Reynier, et al.
Molecular Human Reproduction|August 10, 2004
DNA microarray analysis of gene expression profiles in deep endometriosis using laser capture microdissectionS Matsuzaki, M Canis, C Vaurs-Barrière, et al.
British Journal of Cancer|October 28, 2010
Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancerS Guiu, M Gauthier, B Coudert, et al.
Human Reproduction (Oxford, England)|October 1, 2008
Ovarian epithelial dysplasia after ovulation induction: time and dose effectsG Chene, F Penault-Llorca, G Le Bouëdec, et al.
British Journal of Cancer|January 13, 2006
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?L Arnould, M Gelly, F Penault-Llorca, et al.
British Journal of Cancer|October 2, 2003
Is Nottingham prognostic index useful after induction chemotherapy in operable breast cancer?P Chollet, S Amat, E Belembaogo, et al.
Annals of Surgical Oncology|May 2, 2009
Clinicopathological factors and nomograms predicting nonsentinel lymph node metastases after neoadjuvant chemotherapy in breast cancer patientsP Gimbergues, C Abrial, X Durando, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|October 31, 2006
Correlation between molecular metastases in sentinel lymph nodes of breast cancer patients and St Gallen risk categoryP Gimbergues, M M Dauplat, A Cayre, et al.
Pageof 15

Showing results (71-80 of 141) with videos related to

Sort By:
Pageof 15
ESMO Gastrointestinal Oncology|February 6, 2026
High prevalence of NTRK fusions in sporadic dMMR/MSI mCRC RAS/RAF wild-type: an opportunity for a post-immune checkpoint inhibitors progression rescue strategyM Svrcek, A Cayre, T Samaille, et al.
Biochemical and Biophysical Research Communications|July 13, 2005
Leptin: a proliferative factor for breast cancer? Study on human ductal carcinomaF Caldefie-Chézet, M Damez, M de Latour, et al.
International Journal of General Medicine|April 3, 2010
Role of neo-adjuvant hormonal therapy in the treatment of breast cancer: a review of clinical trialsCatherine Abrial, Xavier Durando, Marie-Ange Mouret-Reynier, et al.
Molecular Human Reproduction|August 10, 2004
DNA microarray analysis of gene expression profiles in deep endometriosis using laser capture microdissectionS Matsuzaki, M Canis, C Vaurs-Barrière, et al.
British Journal of Cancer|October 28, 2010
Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancerS Guiu, M Gauthier, B Coudert, et al.
Human Reproduction (Oxford, England)|October 1, 2008
Ovarian epithelial dysplasia after ovulation induction: time and dose effectsG Chene, F Penault-Llorca, G Le Bouëdec, et al.
British Journal of Cancer|January 13, 2006
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?L Arnould, M Gelly, F Penault-Llorca, et al.
British Journal of Cancer|October 2, 2003
Is Nottingham prognostic index useful after induction chemotherapy in operable breast cancer?P Chollet, S Amat, E Belembaogo, et al.
Annals of Surgical Oncology|May 2, 2009
Clinicopathological factors and nomograms predicting nonsentinel lymph node metastases after neoadjuvant chemotherapy in breast cancer patientsP Gimbergues, C Abrial, X Durando, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|October 31, 2006
Correlation between molecular metastases in sentinel lymph nodes of breast cancer patients and St Gallen risk categoryP Gimbergues, M M Dauplat, A Cayre, et al.
Pageof 15